MIACALCIC 50 IU/ml Injection
Salmon Calcitonin
50 IU/ml
Novartis Pharma AG
| Pack size | 1ml Ampoule x 5 |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | CITY MEDICAL STORE |
| Retail Price | 107.50 AED |
Available as:
Indications
MIACALCIC 50 IU/ml Injection is used for:
Hypercalcaemia, Paget's disease of bone, Postmenopausal osteoporosis.
Adult Dose
Parenteral
Hypercalcemia
Initial dose: 4 IU/kg SC/IM q12hr May increase to 8 IU/kg SC/IM q12hr; may increase up to a maximum 8 IU/kg q6hr if unresponsive
Paget Disease
Initial dose: 100 IU SC/IM qDay
Maintenance: 50 IU/day or 50-100 IU every 1-3 days
Osteoporosis, Postmenopausal
Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 yr postmenopause
100 IU SC/IM every other day with calcium and vitamin D
Nasal Spray:
1 spray (200 IU) qDay, alternate nostrils daily
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Contra Indications
Hypersensitivity.
Precautions
Children <18 yr, renal impairment. Pregnancy, lactation. Serious hypersensitivity reactions, including fatal anaphylaxis, reported; consider skin testing prior to treatment. Hypocalcemia associated with tetany has been reported; ensure adequate intake of calcium and vitamin D
Lactation: excretion in milk unknown/not recommended
Pregnancy-Lactation
Pregnancy
Miacalcin nasal spray is not indicated for use in females of reproductive potential; there are no data with use of in pregnant women; in an animal reproduction study, subcutaneous administration of calcitonin-salmon to pregnant rabbits during organogenesis at 4- 18 times the recommended parenteral human dose caused a decrease in fetal birth weights; no adverse developmental outcome was observed in rat with subcutaneous administration of cal-citonin-salmon at 9 times recommended human parenteral dose based on body surface area
Lactation
Nasal spray is not indicated for use in females of reproductive potential; there is no information on presence in human milk, effects on breastfed child, or on milk production; shown to inhibit lactation in rats
Interactions
Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.
Adverse Effects
Side effects of Salmon Calcitonin :
>10%
Rhinitis (12%)
1-10%
Arthralgia (4%), Back pain (5%), Expistaxis (4%), Injection site reactions (10%), Nausea (10%), Headache (3%), Flushing of face or hands (2-5%)
<1%
Abdominal pain, Possible allergic reactions, Appetite decreased, Edema of feet, Eye pain, Feverish sensation, Nausea, Nocturia, Possible local irritative effects in the respiratory tract, Salty taste
Frequency Not Defined
Tremors
Potentially Fatal: Anaphylactic shock.
Mechanism of Action
It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
Note
MIACALCIC 50 IU/ml 50 IU/ml Injection manufactured by Novartis Pharma AG. Its generic name is Salmon Calcitonin. MIACALCIC 50 IU/ml is availble in United Arab Emirates.
Farmaco UAE drug index information on MIACALCIC 50 IU/ml Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.